Back to results
US 2023/0399362 A1Published application
Interleukin-13 binding cyclic oligopeptides and methods of use thereof
AssigneeB.A.I. Laboratories, LLC
InventorsXuefei Bai, Sheng Lin, Le Li
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also provides methods to treat or prevent IL-13-associated skin disorders or conditions with the IL-13-binding cyclic oligopeptides. The present disclosure further provides methods to produce the IL-13-binding cyclic oligopeptides.
Claims20
A cyclic oligopeptide that binds to IL-13.
A method of producing a cyclic oligopeptide binds to IL-13 comprising the steps of:
- (1) contacting FMOC (9-fluorenylmethyloxycarbonyl)-D-Pro-2cl-resin or FMOC-Pro-2cl-resin with a first amino acid residue under conditions suitable to form a peptide bond between the first amino acid residue and the resin-bound D-Pro or Pro to form a resin-bound oligopeptide;
- (2) washing the resin-bound oligopeptide to remove any unbound amino acid residue;
- (3) contacting the resin-bound oligopeptide with an additional amino acid residue under conditions suitable to form a peptide bond between the additional amino acid residue and the resin-bound oligopeptide;
- (4) washing the resin-bound oligopeptide to remove any unbound amino acid residue;
- (5) removing the resin from the oligopeptide;
- and
- (6) cyclizing the oligopeptide.
4 more elements
Dependencies are inferred from the claim text.